Clinical trial designs for the approval of rare cancer drugs in Japan

被引：0
|
作者：
Noguchi, E. [1 ]
Yonemori, K. [1 ]
Shimoi, T. [1 ]
Yunokawa, M. [1 ]
Okuma, H. S. [2 ]
Kawachi, A. [2 ]
Kitano, A. [3 ]
Nishikawa, T. [2 ]
Shimomura, A. [2 ]
Shimizu, C. [2 ]
Takiguchi, Y. [4 ]
Kawai, A. [5 ]
Fujiwara, Y. [2 ]
Tamura, K. [2 ]
机构：
[1] Natl Canc Ctr, Rare Canc Ctr, Breast & Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Breast & Med Oncol, Tokyo, Japan
[3] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[4] Chiba Univ, Grad Sch Med, Med Oncol, Chiba, Japan
[5] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
154P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Adaptive clinical trial designs for phase I cancer studies
    Sverdlov, Oleksandr
    Wong, Weng Kee
    Ryeznik, Yevgen
    STATISTICS SURVEYS, 2014, 8 : 2 - 44
  • [32] Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in Japan
    Asada, R.
    Shimizu, S.
    Ono, S.
    Ito, T.
    Shimizu, A.
    Yamaguchi, T.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 309 - 313
  • [33] Regulatory approval pathways for anticancer drugs in Japan, the EU and the US
    Nagai, Sumimasa
    Ozawa, Keiya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (01) : 73 - 84
  • [34] Regulatory approval pathways for anticancer drugs in Japan, the EU and the US
    Sumimasa Nagai
    Keiya Ozawa
    International Journal of Hematology, 2016, 104 : 73 - 84
  • [35] EVALUATING DRUGS AFTER THEIR APPROVAL FOR CLINICAL USE
    RAY, WA
    GRIFFIN, MR
    AVORN, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (27): : 2029 - 2032
  • [36] Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023
    Chen, Qi
    Xu, Yang
    Qu, Ruoxuan
    Luo, Xingxian
    Yang, Yue
    DRUG DISCOVERY TODAY, 2024, 29 (09)
  • [37] PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for gastric and biliary tract cancer and encorafenib and binimetinib for thyroid cancer in Japan
    Matsumura, Noriomi
    Mandai, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1053 - 1054
  • [38] Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan
    Kondo, Shunsuke
    Hosoi, Hiroko
    Itahashi, Kota
    Hashimoto, Jun
    CANCER SCIENCE, 2017, 108 (05) : 995 - 999
  • [39] Participation of African Americans in clinical trials supporting FDA approval of cancer drugs.
    Al Hadidi, Samer
    Mims, Martha P.
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti T.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
    Noriomi Matsumura
    Masaki Mandai
    International Journal of Clinical Oncology, 2024, 29 : 493 - 494
12345